Zoonotic & Vector-Borne Diseases

Rising dengue incidence in Puerto Rico signals broadening health concerns.

Phase 2 study of healthcare workers' safety in high-risk populations.

The assay, the cobas Malaria test, is manufactured by Roche, and will be available in the United States at the end of Q2 2024.

The increase highlights the threat posed by climate change and the need for innovative preparedness, prevention, and mitigation tools.

How acute malnutrition undermines Malaria in children under 5 years old.

State health officials did not disclose the origin of transmission.

Climate change's role in the expanding threat of vector-borne diseases.

CDC addresses rising vector-borne diseases with an initiative to enhance public health protection.

Over 1 billion people are estimated to be affected by 20 conditions of neglected tropical diseases (NTDs), though they are often unheard of by many. Heather Saunders, MPH, RN, CIC, delves into 5 of these diseases and discusses efforts to stop their spread.

Trial demonstrates promising results for oral treatment towards the disease's vector.

Innovative treatments, challenging prevention, and impact of climate change.

The impact of the new surveillance criteria on case identification.

A senior microbiologist gives audiences of sister brands, Infection Control Today and Contagion, an insight into leishmaniasis, a potentially fatal disease.

Oregon resident catches plague through a cat-to-human transmission.

First victim of the Alaskapox Virus highlights the need for increased research.

Study offers new insight into the relationship between Zika Virus and Dengue Virus in tropical regions.

Phase 3 trial is highly effective in preventing symptomatic disease.

CDC's preventive strategies against the world's most prevalent mosquito-borne disease.

Study examines the complexity between human health and tick-borne diseases.

A new human trial aims to prevent the fatal, zoonotic-borne disease.

Valneva’s VLA1553 (Ixchiq) vaccine was shown to met its preliminary endpoint, with 98.9% of participants reaching protective levels of chikungunya virus neutralizing antibodies 1 month after vaccination.

When implemented broadly, malaria vaccines can have a significant impact on public health.

The Biden Administration addresses antimicrobial resistance with new project, company voluntarily recalls its antifungal, and a fatal case of the plague is reported in the US.

As we mark this awareness day, education and immunization has helped the United States make great strides in preventing the viral disease, but globally more work needs to be done.

Earlier this year, the company announced its first foray into these types of infections in developing vaccines for the tickborne infection utilizing its mRNA vaccine platform.

The zoonotic virus has claimed 2 lives as Indian officials work to identify potential contacts and get the virus under control.

If approved, the investigational vaccine would be available to people 18 years and older.

The agency says additional time is needed to decide upon a phase 4 program.

With recent reports of this vector-borne illness in the continental United States, there is concern this might become endemic in the country again.

The vaccine is steps behind another Chikungunya vaccine candidate from Valneva, which is currently under priority review by the FDA.